Pfizer CEO Albert Bourla told CNBC on March 11 that the company is developing Omicron (Omicron) that covers the novel coronavirus pneumonia (COVID-19). Rong) and other mutated virus strains.
There are a lot of trials going on right now, he said of the vaccine, and he's optimistic about those preliminary data.
Bra also said the company plans to submit data to the U.S. Food and Drug Administration (FDA) for the fourth dose of the new crown vaccine.
He said that even if life appeared to be partially back to normal, he was still alert to the need to create an effective vaccine.
He said the biggest question for people is how to get ahead of the virus.
He said Pfizer was working on a vaccine that would prevent infection in addition to preventing hospitalizations and severe illness, adding that making a long-acting vaccine was also a priority for the company.
"We can't get vaccinated every five or six months, we need to be able to act early," he said.
Omicron｜Should children get the Pfizer vaccine?
Study: It may not prevent diagnosis, but it is still worth vaccinating with Fubitai | Pfizer applies to FDA to vaccinate children 6 months to under 5 years old for new crown pneumonia | The European Medicines Agency recommends the use of Pfizer's oral drug Paxlovoid for new coronary pneumonia | Pfizer CEO: Yearly doses are better than frequent boosters
